Fairfield, Bush & Co’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-5,720
| Closed | -$269K | – | 113 |
|
|
2024
Q3 | $269K | Sell |
5,720
-305
| -5% | -$14.3K | 0.16% | 92 |
|
|
2024
Q2 | $325K | Buy |
6,025
+1,000
| +20% | +$54K | 0.2% | 79 |
|
|
2024
Q1 | $343K | Buy |
5,025
+2,850
| +131% | +$194K | 0.2% | 86 |
|
|
2023
Q4 | $136K | Buy |
+2,175
| New | +$136K | 0.08% | 129 |
|
|
2023
Q3 | – | Sell |
-5,150
| Closed | -$289K | – | 183 |
|
|
2023
Q2 | $289K | Hold |
5,150
| – | – | 0.08% | 129 |
|
|
2023
Q1 | $233K | Buy |
+5,150
| New | +$233K | 0.08% | 134 |
|
|
2022
Q3 | – | Sell |
-590
| Closed | -$36K | – | 178 |
|
|
2022
Q2 | $36K | Buy |
+590
| New | +$36K | 0.02% | 216 |
|
|
2021
Q4 | – | Sell |
-3,450
| Closed | -$386K | – | 138 |
|
|
2021
Q3 | $386K | Buy |
+3,450
| New | +$386K | 0.13% | 121 |
|